All In Biotech

Drug Trial Radar · NCT06062134

Pericapsular Nerve Group Block: An Imaging Study for Determination of the Spread of the Injectate Using 3-D CT Scan

Last checked: Nov 19, 2026Latest source record: May 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Oct 18, 2023

Primary completion

Dec 21, 2023

Study completion Dec 21, 2023

Sponsor

Lead sponsor
Philippe GauthierAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Over the last 20 years, different interventional regional analgesia techniques have been proposed to treat pain after hip surgeries. The most commonly used techniques are the fascia iliaca and femoral nerve blocks, resulting in reduced pain scores, opioid-sparing effects, and opioid-related adverse effects. However, these interventional analgesia techniques result in a motor block and muscle weakness of the quadriceps muscle, impeding early ambulation and rehabilitation. Recently, the pericapsular nerve group (PENG) block has been proposed as an effective choice for analgesia after hip surgeries while sparing the motor function of the lower extremities. The aim of this technique is to inject local anesthetic to target the more distal sensory branches innervating the anterior aspect of the hip joint.

Conditions

  • Post Operative Pain
  • Mechanisms of Analgesia

Interventions

  • Pericapsular nerve group blockProcedure

    Ultrasound-guided injection of local anesthetic mixed with contrast agent underneath the iliopsoas muscle, lateral to the iliopsoas tendon.

  • 18 mL ropivacaine 0.5% + 2 mL radiopaque contrastDrug

    20 mL of injectate: 18 mL ropivacaine 0.5% + 2 mL radiopaque contrast (Iomeron 300: 61.24% w/v of iomeprol equivalent to 30% iodine or 300 mg iodine/mL)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentration of the local anesthetic reaching specific anatomical areas of interest around the hip jointTime frame: 2 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinique Ste Anne-St Remi

    Brussels, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.